All In Biotech

Drug Trial Radar · NCT01199965

Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers

An Open-Label, 2-Period, Crossover Phase 2 Study Comparing the Pharmacokinetics and Tolerability of Dihydroergotamine Mesylate (DHE) Delivered Intravenously (DHE 45) and by Oral Inhalation (MAP0004) in Smoking and Non-Smoking Adult Volunteers

Last checked: Nov 19, 2026Latest source record: Jan 9, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

47

Actual

Start

Jan 2010

Primary completion

Apr 2010

Study completion Apr 2010

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
Collaborators
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
First posted
Sep 13, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Compare the pharmacokinetics of Dihydroergotamine Mesylate (DHE) delivered by oral inhalation (MAP0004) or Intravenous (IV) DHE in smokers versus non-smokers. Identify whether there are clinically significant differences in the tolerability of MAP0004 between smokers and non-smokers.

Conditions

  • Healthy Subjects

Interventions

  • MAP0004Drug

    1.0mg MAP0004 via inhalation at Visit 2 or 3 as per protocol

  • IV DHEDrug

    IV DHE administered at Visit 2 or 3 as per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax of Dihydroergotamine After MAP0004 and IV DHE Administration in Smokers Versus Non-smokersTime frame: 48 hours
  2. AUC(0-48) of Dihydroergotamine After MAP0004 and IV DHE Administration in Smokers and Non-smokersTime frame: 48 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Simbec Research Limited

    Merthyr Tydfil, Merthyr Tydfil, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.